Ocugen Patient Engagement

Ocugen Patient Engagement A fully integrated, patient-centric biotech company focused on vaccines and gene therapies.

09/01/2026

An important step forward for OCU410 and the millions of people worldwide living with geographic atrophy.

Today, Chairman, CEO, and Co-Founder Shankar Musunuri, PhD, MBA, announced that the first patient has been dosed in our global Phase 3 clinical trial of OCU410. This milestone brings us closer to the potential of a one-time treatment for life and our target of three BLAs by 2028.

Learn more: bit.ly/4qNMBMk

Healthy vision starts with a healthy retina. Learn how geographic atrophy affects the retina and why early awareness mat...
08/19/2026

Healthy vision starts with a healthy retina. Learn how geographic atrophy affects the retina and why early awareness matters.

Follow Ocugen for more educational content on retinal diseases and vision research.

Your vision can change gradually, often without noticeable symptoms. That's why early and regular eye exams are one of t...
08/11/2026

Your vision can change gradually, often without noticeable symptoms. That's why early and regular eye exams are one of the best ways to detect potential vision problems and protect your long-term eye health. Taking action today can help preserve your sight for tomorrow.

Whether you're due for an eye exam or already have one on the calendar, make routine eye care a priority and encourage your loved ones to do the same.

07/27/2026

For years, Manny adapted to the everyday challenges of retinitis pigmentosa, from losing his night vision to relying on loved ones to navigate the world around him. But he never stopped believing in the power of research.

As the third participant to receive OCU400 in a clinical trial, Manny shares how taking a chance on research gave him renewed hope and why he continues to encourage others to consider participating in clinical trials.

Read Manny's story from the Foundation Fighting Blindness: https://bit.ly/3TWCV5S

Stargardt disease affects the retina, the light-sensitive tissue at the back of the eye that plays a critical role in vi...
07/21/2026

Stargardt disease affects the retina, the light-sensitive tissue at the back of the eye that plays a critical role in vision.

Ocugen is advancing OCU410ST, an investigational modifier gene therapy designed as a potential one-time treatment approach for Stargardt disease. By targeting multiple biological pathways associated with the disease, OCU410ST is being evaluated for its potential to preserve retinal structure and visual function.

Learn more about our commitment to patients and their stories: https://bit.ly/4p0fqVc. If you have questions about Stargardt disease, speak with your healthcare provider.

Not all age-related macular degeneration (AMD) is the same.Dry AMD is the more common form and typically progresses slow...
07/10/2026

Not all age-related macular degeneration (AMD) is the same.

Dry AMD is the more common form and typically progresses slowly. Wet AMD is less common but can progress more rapidly.

Geographic atrophy (GA), an advanced form of dry AMD, affects approximately 2–3 million people in the U.S. and Europe combined.

Follow our progress as we advance OCU410, Ocugen's modifier gene therapy candidate for GA. Contact your doctor if you have any concerns.

Understanding how RP affects the retina can provide insight into the vision changes experienced by people living with th...
07/07/2026

Understanding how RP affects the retina can provide insight into the vision changes experienced by people living with the disease.

Ocugen’s OCU400 is an investigational modifier gene therapy designed as a potential one-time treatment for people living with RP.

Learn more about our gene therapy platform and our commitment to inherited retinal diseases: https://bit.ly/4y2y6b0

It’s important to understand the retina and the role it plays in vision. Ocugen is committed to advancing transformative...
06/30/2026

It’s important to understand the retina and the role it plays in vision. Ocugen is committed to advancing transformative gene therapies for people living with inherited retinal diseases and other vision-threatening conditions.

Through scientific innovation and a patient-focused approach, we are developing modifier gene therapies designed to address the underlying causes of these rare conditions and help preserve vision.

Talk to your eye care professional if you notice changes in your vision and follow Ocugen for more educational content about retinal health and vision research.

affects everyone differently. Early signs may include trouble seeing at night, tunnel vision, sensitivity to bright li...
06/25/2026

affects everyone differently. Early signs may include trouble seeing at night, tunnel vision, sensitivity to bright light, or other changes in vision.

If you notice changes in your vision, talk to your doctor.

06/17/2026

“I have more adaptation to light and darkness.” – Nancy

After living with retinitis pigmentosa for 31 years, Nancy shares her story and why she remains hopeful for the future after participating in Ocugen’s OCU400 clinical trial.

Listen to Nancy's story and discover the impact vision can have on everyday life.

To learn more about Ocugen’s novel modifier gene therapy candidates, visit: https://bit.ly/4bjhov5

Address

11 Great Valley Parkway
Malvern, PA
19355

Website

Alerts

Be the first to know and let us send you an email when Ocugen Patient Engagement posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Ocugen Patient Engagement:

Shortcuts

Share

Category